Article
Biochemistry & Molecular Biology
Xiaowei Zhu, Xiangfei Wang, Baoling Zhu, Suling Ding, Hongyu Shi, Xiangdong Yang
Summary: This study reveals the role of the histamine/H1R signaling pathway in doxorubicin-induced cardiotoxicity. Histamine deficiency or H1R antagonism accelerates myocardial ferroptosis and aggravates doxorubicin-induced cardiotoxicity. These findings provide a potential target for the treatment of doxorubicin-induced cardiotoxicity.
FREE RADICAL BIOLOGY AND MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Pei-Ling Hsieh, Pei-Ming Chu, Hui-Ching Cheng, Yu-Ting Huang, Wan-Ching Chou, Kun-Ling Tsai, Shih-Hung Chan
Summary: This study demonstrated that dapagliflozin could mitigate doxorubicin-induced cardiotoxicity by reducing oxidative stress, improving mitochondrial dysfunction, decreasing fibrosis, hypertrophy, and inflammation through the PI3K/AKT/Nrf2 signaling pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Nisar Ahmad, Arfan Ullah, Peng Chu, Wenzhang Tian, Zeyao Tang, Zhaolin Sun
Summary: Doxorubicin is a commonly prescribed chemotherapeutic drug worldwide, but its use is limited by harmful side effects like cardiotoxicity. This review paper focuses on the cardiomyopathy and cardiomyocyte death induced by DOX, as well as the roles of SIRT1, SIRT3, and DOX in modulating mitochondrial processes.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Environmental Sciences
Wei Zhang, Chao Shi, Zhuoya Yao, Shaohuan Qian
Summary: This study reveals the specific mechanism by which bardoxolone methyl alleviates doxorubicin-induced cardiotoxicity by activating the Nrf2 pathway and inhibiting the TXNIP-NLRP3 pathway. Bardoxolone methyl reduces oxidative stress and pyroptosis, thereby alleviating myocardial damage and cardiac fibrosis.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Pharmacology & Pharmacy
Thawatchai Khuanjing, Benjamin Ongnok, Chayodom Maneechote, Natthaphat Siri-Angkul, Nanthip Prathumsap, Apiwan Arinno, Titikorn Chunchai, Busarin Arunsak, Siriporn C. Chattipakorn, Nipon Chattipakorn
Summary: The study showed that donepezil can alleviate doxorubicin-induced cardiotoxicity, reduce cardiac damage, and improve cardiac function.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Cell Biology
Weili Li, Xiaoping Wang, Tianhua Liu, Qian Zhang, Jing Cao, Yanyan Jiang, Qianbin Sun, Chun Li, Wei Wang, Yong Wang
Summary: Doxorubicin is an effective chemotherapeutic agent, but its clinical use is limited due to the severe risk of cardiotoxicity. This study finds that harpagoside has significant cardioprotective effects in DICT mouse and rat cardiomyocytes by targeting the interaction between p53 and Parkin to restore mitophagy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Jie Wang(a), Jingjing Zhang, Mengjie Xiao, Shudong Wang, Jie Wang(b), Yuanfang Guo, Yufeng Tang, Junlian Gu
Summary: Doxorubicin is a commonly used chemotherapy drug, but its cardiotoxicity limits its clinical application. Recent studies have found that pre-treatment with dexrazoxane cannot fully improve the myocardial toxicity of doxorubicin, highlighting the need for more targeted cardioprotective strategies.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Mingge Ding, Rui Shi, Shuli Cheng, Man Li, Dema De, Chaoyang Liu, Xiaoming Gu, Juan Li, Shumiao Zhang, Min Jia, Rong Fan, Jianming Pei, Feng Fu
Summary: This study found that inhibition of Mfn2-mediated mitochondrial fusion is associated with cardiac dysfunction and tumorigenesis. Restoring Mfn2-mediated mitochondrial fusion can enhance mitochondrial oxidative metabolism, reduce cellular injury and oxidative stress, and provide a dual therapeutic advantage in Dox-based chemotherapy by defending against Dox-induced cardiotoxicity and boosting its antitumor potency.
Review
Environmental Sciences
Xiaofeng Li
Summary: Although chemotherapy drugs are widely used in cancer treatment, their administration has faced problems such as chemoresistance and concentration-related toxicity. Doxorubicin (DOX) is an effective drug for tumor treatment, but it can also cause side effects and cardiac toxicity. The paper discusses the mechanism of DOX-mediated toxicity and explores the use of drugs and nanotherapeutics to alleviate cardiovascular diseases caused by DOX.
ENVIRONMENTAL RESEARCH
(2023)
Article
Chemistry, Multidisciplinary
Lindomar J. C. Albuquerque, Vladimir Sincari, Alessandro Jager, Jan Kucka, Jana Humajova, Jan Pankrac, Petr Paral, Tomas Heizer, Olga Janouskova, Irina Davidovich, Yeshayahu Talmon, Pavla Pouckova, Petr Stepanek, Ludek Sefc, Martin Hruby, Fernando C. Giacomelli, Eliezer Jager
Summary: This study demonstrates the use of pH-responsive polymersomes for successful loading and release of doxorubicin in tumor microenvironments, leading to enhanced therapeutic efficacy and increased survival rate in mice.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Biotechnology & Applied Microbiology
Hong Zhu, Min He, Yong-Li Wang, Yuanxin Zhang, Jingsong Dong, Bo-Yan Chen, Yu-Lin Li, Lu-Jun Zhou, Lin-Juan Du, Yuan Liu, Wu-Chang Zhang, Dean Ta, Sheng-Zhong Duan
Summary: Low-intensity pulsed ultrasound (LIPUS) therapy protects against doxorubicin (DOX)-induced cardiotoxicity by inhibiting S100a8/a9-mediated neutrophil recruitment and infiltration. This study suggests the potential application of LIPUS therapy in cancer patients undergoing DOX chemotherapy.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2023)
Article
Chemistry, Multidisciplinary
Durairaj Siva, Subramanian Abinaya, Durairaj Rajesh, Govindaraju Archunan, Parasuraman Padmanabhan, Balazs Gulyas, Shanmugam Achiraman
Summary: This study investigates the possible mechanism of doxorubicin-mediated cardiotoxicity and explores the use of chitosan nanoparticles conjugated with doxorubicin and supplemented with propionic acid to reduce the cardiotoxicity. The results show that DCNPs and propionic acid have a protective effect against doxorubicin-induced cardiotoxicity.
Review
Pharmacology & Pharmacy
Isobel C. Jones, Crispin R. Dass
Summary: Doxorubicin is widely used as a chemotherapeutic agent, but its cardiotoxicity limits its application. The understanding of Doxorubicin metabolism and mechanisms of action is still incomplete, and the mechanisms of Doxorubicin-induced cardiotoxicity are multifactorial and involve oxidative stress. Novel delivery systems and antioxidant therapies are important for reducing cardiotoxicity.
JOURNAL OF PHARMACY AND PHARMACOLOGY
(2022)
Article
Plant Sciences
Bo Chen, Jing-Pu Zhang
Summary: BBR can alleviate DOX-induced cardiotoxicity by balancing cardiomyocyte autophagy and apoptosis. It exhibits biphasic dose-response effects in response to DOX, and the protective effects are mediated by Bcl-xL.
Article
Oncology
Xiao-yi Du, Dao-chun Xiang, Ping Gao, Hua Peng, Ya-li Liu
Summary: PRR inhibition can weaken the RAC1-NOX4 pathway and alleviate DOX-induced heart failure by reducing ROS production.
FRONTIERS IN ONCOLOGY
(2022)